Cargando…
S234: UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
Autores principales: | Chen, Xinfeng, Ping, Yu, LI, Ling, Zhang, Lei, Zhang, Xudong, Huang, Jianmin, Liu, Jia, LI, Gui, He, Jiaping, Zhang, Hua, Zhao, Wei, Weng, Lihong, Yin, Wenjie, Shen, Lianjun, Cao, Wei William, LI, Wenling, Zhang, Mingzhi, Zhang, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428513/ http://dx.doi.org/10.1097/01.HS9.0000967848.32931.92 |
Ejemplares similares
-
P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Du, Juan, et al.
Publicado: (2023) -
P1218: FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
por: Chen, X., et al.
Publicado: (2022) -
Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
por: Li, Dan, et al.
Publicado: (2022) -
AB012. Involvement of elevated TRPC6 in pathogenesis of overactive bladder
por: Wang, Ping, et al.
Publicado: (2015) -
Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)